Three potentially fatal adverse effects of psychotropic medications

Perspectives in Psychiatric Care

Volumn 39, Issue 2, 2003, Pages 75-81

  Wren, Pamelia ^b   Frizzell, Laura A ^b   Keltner, Norman L ^a   Wright, Amy V ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE

Author keywords

Agranulocytosis; Neuroleptic malignant syndrome; Psychotropics; Serotonin syndrome

Indexed keywords

AMITRIPTYLINE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CYPROHEPTADINE; DEXAMPHETAMINE; FENTANYL; FLUOXETINE; FLUVOXAMINE; LINEZOLID; METOCLOPRAMIDE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; RISPERIDONE; SELEGILINE; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; TANDOSPIRONE; TRAMADOL; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; AGRANULOCYTOSIS; AUTONOMIC DYSFUNCTION; CATATONIA; COMA; DELIRIUM; DYSKINESIA; DYSTONIA; HUMAN; NEUROLEPTIC MALIGNANT SYNDROME; PATHOPHYSIOLOGY; REVIEW; RHABDOMYOLYSIS; SEROTONIN SYNDROME; TREMOR;

EID: 0041565257     PISSN: 00315990     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1744-6163.2003.tb00679.x     Document Type: Review

References (30)

1. Alphs, L., & Anand, R. (1990) Clozapine: The commitment to patient safety. Journal of Clinical Psychiatry, 60(Suppl. 12), 39-42.
2. Beauchemin, M.A., Millaud, F., & Nguyen, K.A. (2002). A case of neuroleptic malignant syndrome with clozapine and risperidone. Canadian Journal of Psychiatry, 47, 886.
3. Clozaril [package insert]. (1998). East Hanover, NJ: Novartis Pharmaceuticals Corp.
4. Feldman, J. (1996). Clozapine and agranulocytosis. Psychiatric Services, 47, 1177-1178.
5. Gaszner, P., Makkos, Z., & Kosza, P. (2002). Agranulocytosis during clozapine therapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 26, 603-607.
6. Gerson, S.L. (1994). G-CSF and the management of clozapine-induced agranulocytosis. Journal of Clinical Psychiatry, 55(Suppl. B), 139-142.
7. Guest, I,. & Sokoluk, B. (1998). Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology, 131, 53-65.
8. Harradine, P.G., Williams, S.E., & Doherty, S.R. (2001). Neuroleptic malignant syndrome: An underdiagnosed condition. Medical Journal of Australia, 174, 593-594.
9. Keltner, N.L. (1997a). Catastrophic consequences secondary to psychotropic drugs, Part I. Journal of Psychosocial Nursing and Mental Health Services, 35(4), 41-45.
10. Keltner, N. (1997b). Catastrophic consequences secondary to psychotropic drugs, Part 2. Journal of Psychosocial Nursing and Mental Health Services, 35(5), 48-50.
11. Keltner, N.L., Hogan, B., & Guy, D.M. (2001). Dopaminergic and serotonergic receptor function in the CNS. Perspectives in Psychiatric Care, 37, 65-72.
12. Keltner, N.L., & McIntyre C.W. (1985). Neuroleptic malignant syndrome. Journal of Neurosurgical Nursing, 17, 362-366.
13. Kuszmar, T.J., Blasiole, D., & Schwartz, K. (1998, November). Selective serotonin reuptake inhibitors: How safe are they? Physician Assistant, 22(11), 47-48, 51-52, 54, 57.
14. Lappa, A., Podesta, M., Capelli, O., Castagna, A., Di Placido, G., Alampi, D., et al. (2002). Successful treatment of a complicated case of neuroleptic malignant syndrome. Intensive Care Medicine, 28, 976-977.
15. Lieberman, J.A., Yunis, J., Egea, E., Canoso, R.T., Kane, J.M., & Yunis, E.J. (1990). HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry, 47, 945-948.
16. Mason, P.J., Morris, V.A., & Balcezak, T.J. (2000). Serotonin syndrome: Presentation of 2 cases and review of the literature. Medicine, 79, 201-209.
17. McKenry, L.M., & Salerno E. (1998). Pharmacology in nursing (20th ed.). St. Louis, MO: Mosby.
18. Mendelowitz, A.J., Gerson, S.L., Alvir, J.M.J., & Lieberman, J.A., (1995). Clozapine-induced agranulocytosis: Risk factors, monitoring, and management. CNS Drugs, 4, 412-421.
19. Oates, J.A., & Sjoerdsma, A. (1960). Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology, 10, 1076-1078.
20. Persing, J.S. (1994, February). Neuroleptic malignant syndrome: An overview. University of South Dakota School of Medicine.
21. Philibert, R.A., Adam, L.A., Frank, F.M., & Carney-Doebbeling, C. (2001). Olanzapine usage associated with neuroleptic malignant syndrome. Psychosomatics, 42, 528-529.
22. Radomski, J.W., Dursun, S.M., Reveley, M.A., & Kutcher, S.P. (2000). An exploratory approach to the serotonin syndrome: An update of clinical phenomenology and revised diagnostic criteria. Medical Hypotheses, 55, 218-224.
23. Reeves, R.R., Mack, J.E., & Torres, R.A. (2001). Neuroleptic malignant syndrome during a change from haloperidol to risperidone. Annals of Pharmacology, 35, 698-700.
24. Reeves, R.R., Torres, R.A., Liberto, V., & Hart, R.H. (2002). Atypical neuroleptic malignant syndrome associated with olanzapine. Pharmacotherapy, 22, 641-644.
25. Rosebush, P. (1994). What is neuroleptic malignant syndrome and how is it treated? Harvard Mental Health Letter, 11(6), 8.
26. Rudolf, J., Grond, M., Neveling, M., & Heiss, W.D. (1997). Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis. Journal of Neural Transmission, 104, 1305-1311.
27. Solomons, K. (2002). Quetiapine and neuroleptic malignant syndrome. Canadian Journal of Psychiatry, 47, 791.
28. Sternbach, H. (1991, June). The serotonin syndrome. American Journal of Psychiatry, 148, 705-713.
29. Theodoropoulou, S., Pappa, H., Lykouras, L., Papagecrgiou, G., Papasteriades, C., & Sakalis, G. (1997). Human leukocyte antigen system in clozapine-induced agranulocytosis. Neuropsychobiology, 36, 5-7.
30. Witzel, C., & Jiwanlal, S. The darker side of SSRIs. RN, 64(8), 43-47.